Zobrazeno 1 - 10
of 93
pro vyhledávání: '"GIACOMO RUOTOLO"'
Autor:
Divyang R Patel, Julie St John, Jeffrey Riesmeyer, Govinda Weerakkody, Giacomo Ruotolo, Kathy E Wolski, Ellen McErlean, Stephen J Nicholls, A Michael Lincoff, Steven E Nissen
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 8, Iss 1 (2020)
BackgroundHigh-density lipoprotein (HDL) levels are inversely associated with cardiovascular risk. Cholesteryl ester transfer protein inhibition with evacetrapib results in a marked increase in HDL and reduction in low-density lipoprotein (LDL) level
Externí odkaz:
https://doaj.org/article/1c39cdf2cf5d43bc8b64e46790a8c81b
Autor:
Venu Menon, Anirudh Kumar, Divyang R. Patel, Julie St. John, Kathy E. Wolski, Ellen McErlean, Jeffrey S. Riesmeyer, Govinda Weerakkody, Giacomo Ruotolo, Paul C. Cremer, Stephen J. Nicholls, A. Michael Lincoff, Steven E. Nissen
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 1 (2020)
Background The contemporary impact of glycemic control on patients with diabetes mellitus at high cardiovascular risk remains unclear. We evaluated the utility of hemoglobin A1c (HbA1c) as a marker of risk on the composite end point of cardiovascular
Externí odkaz:
https://doaj.org/article/851ccfb81c9944149d295702a4eae73b
Autor:
Anirudh Kumar, Divyang R. Patel, Danielle M. Brennan, Kathy E. Wolski, A. Michael Lincoff, Giacomo Ruotolo, Ellen McErlean, Govinda Weerakkody, Jeffrey S. Riesmeyer, Stephen J. Nicholls, Steven E. Nissen, Venu Menon
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 23 (2019)
Background The failure of cholesteryl ester transfer protein inhibitor torcetrapib was associated with an off‐target increase in plasma aldosterone. We sought to evaluate the impact of evacetrapib on plasma aldosterone level and determine the assoc
Externí odkaz:
https://doaj.org/article/11a1cfdcc6d2471fa5475695b4686ecc
Autor:
Marina Cuchel, Anna C. Raper, Donna M. Conlon, Daniel A. Pryma, Richard H. Freifelder, Rahul Poria, Debra Cromley, Xiaoyu Li, Richard L. Dunbar, Benjamin French, Liming Qu, William Farver, Ching-Chiang Su, Sissel Lund-Katz, Amanda Baer, Giacomo Ruotolo, Peter Akerblad, Carol S. Ryan, Lan Xiao, Todd G. Kirchgessner, John S. Millar, Jeffrey T. Billheimer, Daniel J. Rader
Publikováno v:
Journal of Lipid Research, Vol 58, Iss 4, Pp 752-762 (2017)
Reverse cholesterol transport (RCT) is thought to be an atheroprotective function of HDL, and macrophage-specific RCT in mice is inversely associated with atherosclerosis. We developed a novel method using 3H-cholesterol nanoparticles to selectively
Externí odkaz:
https://doaj.org/article/50852041bbb149b0ab71cadc9ddee278
Autor:
Franco Pagani, Rajalakshmi Pariyarath, Rodolfo Garcia, Cristiana Stuani, Alberto B. Burlina, Giacomo Ruotolo, Marco Rabusin, Francisco E. Baralle
Publikováno v:
Journal of Lipid Research, Vol 39, Iss 7, Pp 1382-1388 (1998)
Deficiency of lysosomal acid lipase (LAL) leads to either Wolman disease(WD) or the more benign cholesteryl ester storage disease (CESD). To identifythe molecular basis of the different phenotypes we have characterised the LALgene mutations in three
Externí odkaz:
https://doaj.org/article/f39de1ef260947fe85ff4d95446aef87
Autor:
Hertzel C. Gerstein, Shun-Fu Lee, Guillaume Paré, M. Angelyn Bethel, Helen M. Colhoun, Anastasia Hoover, Mark Lakshmanan, Yanzhu Lin, Valentino Pirro, Hui-Rong Qian, Giacomo Ruotolo, Lars Ryden, Jonathan M. Wilson, Kevin L. Duffin
OBJECTIVE The glucagon-like peptide-1 receptor agonist dulaglutide reduced MACE in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. This article expores the relationship of selected biomarkers to both dulagluti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2640ca757c8cf50993017da4bd7b9737
https://doi.org/10.2337/figshare.22120097
https://doi.org/10.2337/figshare.22120097
Autor:
Jeremy D. Furtado, Giacomo Ruotolo, Stephen J. Nicholls, Robert Dullea, Santos Carvajal-Gonzalez, Frank M. Sacks
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology
Supplemental Digital Content is available in the text.
Objective: Plasma total HDL (high-density lipoprotein) is a heterogeneous mix of many protein-based subspecies whose functions and associations with coronary heart disease vary. We hypothesi
Objective: Plasma total HDL (high-density lipoprotein) is a heterogeneous mix of many protein-based subspecies whose functions and associations with coronary heart disease vary. We hypothesi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce678dd1c43d1e76cd7dcd9a44d9efac
http://europepmc.org/articles/PMC8785774
http://europepmc.org/articles/PMC8785774
Autor:
Kenneth D. Roth, Valentina Pirro, Kevin L. Duffin, Jonathan M. Wilson, Yanzhu Lin, Jill A. Willency, Axel Haupt, Paul L. Milligan, Christopher B. Newgard, Giacomo Ruotolo
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 107:363-378
Context Tirzepatide substantially reduced hemoglobin A1c (HbA1c) and body weight in subjects with type 2 diabetes (T2D) compared with the glucagon-like peptide 1 receptor agonist dulaglutide. Improved glycemic control was associated with lower circul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3140a92fd3671aef505b0ff756594a2c
https://doi.org/10.1210/clinem/dgab722
https://doi.org/10.1210/clinem/dgab722
Autor:
JONATHAN M. WILSON, GUILLAUME PARE, SHUN FU LEE, HELEN M. COLHOUN, HUI-RONG QIAN, VALENTINA PIRRO, ANASTASIA HOOVER, MARK LAKSHMANAN, GIACOMO RUOTOLO, KEVIN L. DUFFIN, HERTZEL C. GERSTEIN
Publikováno v:
Diabetes. 71
In the REWIND trial, dulaglutide (DU) reduced the risk of CV outcomes compared with placebo (PL) (Major Adverse Cardiovascular Event [MACE]-3 hazard ratio 0.88) . This post hoc analysis studied circulating protein biomarkers associated with CV events
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::406a813d146475b65a3c3fbd37a0f23f
https://doi.org/10.2337/db22-725-p
https://doi.org/10.2337/db22-725-p
Autor:
Jonathan M. Wilson, Axel Haupt, Deborah A. Robins, Marja-Riitta Taskinen, William C. Roell, Giacomo Ruotolo, Jeffrey S. Riesmeyer, Amir Nikooienejad, Kevin L. Duffin
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To better understand the marked decrease in serum triglycerides observed with tirzepatide in patients with type 2 diabetes, additional lipoprotein-related biomarkers were measured post hoc in available samples from the same study. Materials and M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::827cbd0658b18b861b1a4dc00936b7d2
https://doi.org/10.1111/dom.14174
https://doi.org/10.1111/dom.14174